Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate

(Article begins on next page)

19 April 2024

Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with Enzalutamide or Abiraterone Acetate

Rosario F. Di Stefano[1], Marcello Tucci[2]*, Fabio Turco[1], Alessandro Samuelly[1], Maristella Bungaro[1], Chiara Pisano[1], Francesca Vignani[3], Mara Gallicchio[1] Giorgio V. Scagliotti[1], Massimo Di Maio[3], Consuelo Buttigliero[1].

[1]Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano, Turin, Italy

[2]Medical Oncology Department, Cardinal Massaia Hospital, Asti, Italy

[3]Department of Oncology, University of Turin, at Division of Medical Oncology, Ordine Mauriziano Hospital, Via Magellano 1, 10028 Turin, Italy

*Corresponding author:

Marcello Tucci, MD

Department of Medical Oncology

Cardinal Massaia Hospital, Corso Dante Alighieri, 202

14100 Asti (AT), Italy

Phone: +393286754734

E-mail: marcello.tucci@gmail.com

21   **Conflict of Interest**

22   This research did not receive any specific grant from funding agencies in the public, commercial, or

23   not-for-profit sectors.

Abstract:

Background: Our retrospective study aims to evaluate the prognostic role of duration of response to androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC) patients treated with enzalutamide (E) or (AA).

Materials and Methods: Patients were divided in 3 groups according to ADT response (group 1 [G1]:<12 months; group 2 [G2]: 12-36 months; group 3 [G3]: >36 months). Outcome measures were progression-free survival (PFS) and overall survival (OS).

Results: Patients with longer ADT response had better OS (median 17.3 months G1, 19.9 months G2, 31.6 months G3; HR G3 vs G1 0.41, 95%CI 0.25-0.64; p= 0.001) and better PFS (median 5.9 m G1, 8.8 months G2, 11.7 months G3; HR G3 vs G1 0.41, 95%CI 0.41-0.27; p<0,001). In docetaxel naive patients, median OS was 18.8 in G1, 35.2 in G2 and not reached in G3 (HR G3 vs G1 0.33, 95%CI 0.14-0.78; p = 0.038), median PFS was 7 months G1, 9.3 months G2 and 20 months G3 (HR G3 vs G1 0.31, 95%CI 0.15-0.62; p = 0.003). In post-docetaxel patients median OS was 13.1 months in G1, 17.2 months in G2 and 21.4 months in G3 (HR G3 vs G1 0.52, 95%CI 0.29-0.94; p = 0.082), while median PFS was 5.2 months in G1, 6.8 months in G2 and 8.3 months in G3 (HR G3 vs G1 0.54, 95%CI 0.32-0.91; p = 0.067).

Conclusions: Duration of ADT response is an independent prognostic factor of outcome with AA or E.

Keywords: castration resistant prostate cancer; androgen deprivation therapy; abiraterone acetate; enzalutamide; prognosis.

Introduction:

Androgen deprivation therapy (ADT) is the mainstay of therapy for metastatic prostate cancer (PC) patients[1]. Unfortunately, many patients eventually progress to the castrate-resistant prostate cancer (CRPC) phase[2]. Despite the therapeutic effects of new hormonal agents (NHAs) in CRPC, a significant percentage of patients are primarily resistant or acquire resistance. About ~~1/3~~ 30% of patients treated with abiraterone acetate (AA)[5] and ~~20% of those treated with~~ Enzalutamide (E)[8] develop a disease progression within three months from initiation. Considering the lack of head-to-head studies comparing the different therapeutic agents, guiding the choice of the most effective drug for each patient, there is an urgent need to identify prognostic factors of response to NHAs. Several prognostic models have been developed to predict overall survival (OS)[10-17] in mCRPC patients. In particular, Halabi's model[12] included eight variables: Eastern Cooperative Oncology Group Performance Status (ECOG PS), albumin, haemoglobin, prostate specific antigen (PSA), Alkaline phosphatase (ALP), lactate dehydrogenase (LDH) level and opioids use[13]. Recently, Armstrong at al (Annals 2018 e Eur Ur 2020), analyzing patients from PREVAIL trial, published an internally validated prognostic model that stratifies men with mCRPC into three risk groups. This model identified 11 key independent OS prognostic factors, and included a nomogram and a risk group calculator for predicting 1-, 2-, and 3-yr for patients with mCRPC treated with enzalutamide in the PREVAIL trial. Some clinical data indicate that the duration of ADT response influences outcome of first-line NHAs therapy[13-21] in mCRPC patients. Giacinti et al.[18] showed that the duration of ADT response did not affect progression-free survival (PFS) in 59 patients treated with AA. Conversely, the studies by Loriot[19] and McKay[20] demonstrated that a duration of ADT response less than 12 months worsened median overall response and OS in mCRPC patients and the COU-AA02 trial showed an increased radiographic PFS in patients with longer prior exposure to ADT within both treatment groups[21]. Nakabayashi et al[22] showed that those who had received

69   ADT more than 24 months received secondary next-generation hormonal therapy for a median

70   duration of 40.0 months, whereas men who had developed resistance to ADT in less than 24

71   months had a median therapy duration of 18.4 months (P < .0001). Li et al[23] demonstrated that

72   longer ADT duration correlated with better OS and greater PFS in a series of 64 patients treated

73   with AA. Similarly, other small series [24-26] demonstrated that the duration of primary ADT could

74   represent a predictive factor of response to AA or E. Moreover, it is well defined as AR play a main

75   role in CRPC. NHAs interfere with AR pathway inhibiting the PC androgens synthesis (31,32) or

76   preventing AR translocation (33). Considering these mechanisms, PC that are less dependent on

77   AR signalling might be expected to have shorter ADT response duration, as an index of hormone

78   responsiveness of disease, and worse outcomes with subsequent AR-targeted therapy. The aim of

79   this work is to evaluate the role of ADT response duration as prognostic factor in patients with

80   mCRPC treated with NHAs, both in chemo-naive and chemo-pretreated patients.

81

82   **Materials and methods**

83   *Population*

84   All mCRPC patients treated at the Division of Medical Oncology at San Luigi Gonzaga Hospital in

85   Orbassano (Turin) between January 2010 and December 2018 who received AA or E were

86   evaluated for eligibility for this retrospective study. If patients received both AA and E, only data of

87   the first NHA treatment were considered in this analysis.

88   CRPC was defined as disease progression despite ADT and may present as either a continuous rise

89   in serum PSA levels with serum testosterone <50 ng/dL with/without the progression of pre-

90   existing disease and/or the appearance of new metastases. All patients were treated with

91   continuous ADT (LHRH agonist or antagonist). ADT response duration was defined as the time

92   from the start of the ADT until the onset of the CRPC.

93 The baseline data collected were: treatment setting (docetaxel-naïve or docetaxel-pretreated),

94 new generation hormonal drug (AA or E), age, ECOG PS, PSA, hemoglobin, albumin, ALP, LDH,

95 analgesic opioids use, presence of visceral metastases. We collected outcome and follow-up data

96 including best biochemical (PSA) response, date of disease progression, type of disease progression

97 (clinical, instrumental, or biochemical), and date of death or date of last follow-up visit.

98 *Statistical analysis*

99 For this analysis, patients were categorized in three groups according to ADT duration of response:

100 group 1 (progression within 12 months), group 2 (progression between 12 and 36 months) and

101 group 3 (progression after 36 months). Descriptive statistics for the patient groups were reported

102 as percentages for categorical variables, and as median and range for continuous variables. We

103 used χ^2-test or Fisher exact test (as appropriate) for categorical variables and Wilcoxon-Mann-

104 Whitney test for continuous variables to compare baseline characteristics among prognostic

105 groups. The outcome measures were PFS and OS. PFS was defined as the time from the date of

106 NHA treatment beginning to the date of clinical, biochemical and/or instrumental progression, or

107 the date of death for patients who died without known progression, or the last date of follow-up

108 for patients alive without progression. OS was defined as the time from the date of NHA treatment

109 beginning to the date of death, or the last date of follow-up for alive or lost patients. The Kaplan-

110 Meier method was used to calculate PFS and OS; the log rank test was used to compare the

111 outcome among groups. The comparison among the groups was carried out in the overall

112 population (patients treated with AA or E, in the Docetaxel-naïve setting or Docetaxel-pretreated);

113 in the subgroups of patients treated with AA or E in the Docetaxel-naïve setting; in the subgroup of

114 patients treated with AA or E pre-treated with Docetaxel. To assess the prognostic role of ADT

115 duration, univariable and multivariable analysis were conducted, using the Cox regression model.

116 To perform multivariable analysis, we considered all parameters validated in Halabi's nomogram,

presence or absence of visceral metastases, new-generation hormonal drug (AA or E) and treatment settings (Docetaxel-naïve or Docetaxel-pretreated). All statistical tests were 2-tailed and P values < .05 were considered statistically significant. Subgroup analyses were exploratory and no correction for multiple testing was performed. Analyses were done with IBM SPSS for Windows, Version 25.0.

Results

Overall, data about ADT start and duration were available in 255 (82%) of 311 patients treated with AA or E. Baseline characteristics of eligible patients are described in table 1.

In detail, 140 (54.9%) received AA and 115 patients (45.1%) received E. The median age was 73 years (range: 50-89 years). 118 patients (46.3%) had been treated with docetaxel before the administration of NHA, while the remaining 137 (53.7%) were docetaxel-naïve. Use of AA and E was significantly unbalanced between the 2 settings: namely, 61.4% of patients treated with AA were pretreated with docetaxel, vs. 27.8% of patients treated with E. About 95% of patients had ECOG PS 0 or 1 at baseline. Patients with visceral metastases were 32 (12.6%), and 74 (32.6%) patients were assuming opioids to control pain. Median ADT duration response was 31.0 months (0.36-250.1).

Table 2 shows patients baseline characteristics divided into three populations: 41 (16.1%) patients in group 1(17 in docetaxel-naïve and 24 in post-Docetaxel setting), 106 (41.6%) patients in group 2(61 in docetaxel-naïve and 45 in post-Docetaxel setting) and 108 (42.4%) patients in group 3 (59 in docetaxel-naïve and 49 in post-Docetaxel setting). We found statistically significant differences between the three groups in age (p <0.001), opioids use (p = 0.030), baseline ALP (p = 0.014) and baseline LDH (p = 0.006). The baseline differences in opioid use suggest that the groups might be

7

140   mismatched for other factors not measured. Namely, patients with longer ADT duration were

141   significantly older, with lower values of baseline ALP and LDH and were assuming less opioids.

142   *Overall Survival*

143   Kaplan-Meier curves for OS according to duration of ADT response category are shown in figure

144   1a. Median OS was 17.3 months in group 1 (95%CI, 8.9 - 25.6), 19.9 months in group 2 (95%CI,

145   12.8 - 27.1) and 31.6 months in group 3 (95%CI, 19.3 – 43.9). Probability of being alive at 24

146   months was 31.3%, 45.3% and 56.4%, respectively. Hazard ratio (HR) for group 2 vs group 1 was

147   0.64 (95% CI, 0.40-1.02). HR for group 3 vs group 1 was 0.41 (95% CI, 0.25 – 0.66); Total p-value

148   was 0.001. Kaplan-Meier curves for OS according to duration of ADT response category in patients

149   who received AA or E being docetaxel-naïve are shown in figure 2a. In this subgroup, median OS

150   was 18.8 months in group 1 (95%CI, 13.6 – 24.0), 35.2 months in group 2 (95%CI, 16.1 - 54.2) and

151   was not reached in group 3. Probability of being alive at 24 months was 39.2%, 50.7% and 70.1%,

152   respectively. HR for group 2 vs group 1 was 0.57 (95%CI, 0.26 – 1.28). HR for group 3 vs group 1

153   was 0.33 (95%CI, 0.14-0.78). Total p-value was 0.038. Kaplan-Meier curves for OS according to

154   duration of ADT response category in Docetaxel-pretreated patients are shown in figure 2b. In

155   Docetaxel-pretreated patients, median OS for group 1 was 13.2 months (95%CI, 1.8 - 24.6); for

156   group 2 was 17.2 months (95%CI, 12.4 – 22.0) and for group 3 was 21.4 months (95%CI, 17.5 -

157   25.2). Probability of being alive at 24 months was 26.7%, 40.0% and 44.2%, respectively. HR for

158   group 2 vs group 1 was 0.72 (95%CI, 0.41 – 1.28). HR for group 3 vs group 1 was 0.52, (95%CI, 0.29

159   – 0.94). Total p-value was 0.082. Kaplan-Meier curves for OS according to duration of ADT

160   response category in AA treated patients are shown in figure 4a. Among patients treated with AA,

161   median OS was 17.3 in group 1 (95%CI, 9.5 - 25.1), 16.3 in group 2 (95%CI, 14.3 - 18.2) and 25.5 in

162   group 3 (95%CI, 13.3 - 37.7). Probability of being alive at 24 months was 22.6%, 27.3% and 52.1%,

163   respectively. HR for group 2 vs group 1 was 0.71 (95% CI, 0.41-1.25). HR for population 3 vs

population 1 was 0.38 (95% CI, 0.22-0.67). Total p-value was 0.001. Kaplan-Meier curves for OS

according to duration of ADT response category in E treated patients are shown in figure 4b. In

patients treated with E, median OS for group 1 was 20.7 (95%CI, not estimable), for group 2 was

34.6 (95%CI, 23.6 - 45.6) and in group 3 was 41.1 (95%CI, 21.7 - 60.4). Probability of being alive at

24 months was 45.4%, 69.5% and 67.0%, respectively. HR for population 2 vs population 1 was

0.56 (95% CI, 0.24-1.30). HR for population 3 vs population1 was 0.37 (95% CI, 0.14-0.96). Total p-

value was 0.121.

The multivariable analysis (adjusted for baseline PSA, ALP, LDH, hemoglobin, albumin, ECOG PS,

use of opioids, presence of visceral disease) showed that basal PSA value (HR for higher vs lower

PSA 1.86, 95%CI 1.19 - 2.89, p=0.006), ECOG PS (HR for PS 1 vs 0 2.14; 95%CI 1.40 - 3.27), the

duration of the response to ADT (HR for group 2 vs 1 0.74, 95% CI 0.42 – 1.30; HR for group 3 vs 1

0.45, 95%CI 0.26 - 0.79; p = 0.013) are independent variables associated with the OS (table 3).

Progression free survival

Kaplan-Meier curves for PFS according to duration of ADT response category are shown in figure

1b. Median PFS was 6.0 months (95%CI, 5.0 – 6.9) in group 1, 8.8 months (95%CI, 7.21-10.34) in

group 2 and 11.7 months (95%CI, 10.0 - 13.4) in group 3, respectively. Probability of being

progression-free at 12 months was 15.7%, 36.1%, 47.5%, respectively. HR for group 2 vs group 1

was 0.56 (95% CI, 0.37-0.85). HR for group 3 vs group 1 was 0.41 (95% CI, 0.27 – 0.62; total p-value

was < 0.001. In Docetaxel-naive patients (figure 3a), the median PFS for group 1 was 7.0 months

(95%CI, 4.8-9.1), for group 2 was 9.3 months (95%CI, 7.0-11.7) and for group 3 was 20.0 months

(95%CI, 11.4-28.5). Probability of being progression-free at 12 months was 17.7%, 41.1% and

66.4%, respectively.HR for group 2 vs group 1 was 0.57 (95% CI, 0.30-1.11). HR for group 3 vs

group 1 was 0.31 (95% CI, 0.15 – 0.62); total p-value was 0.003. Kaplan-Meier curves for PFS

according to duration of ADT response category in Docetaxel-pretreated patients are shown in

188 figure 3b. In Docetaxel-pretreated patients, median PFS was 5.2 months in group 1 (95%CI, 3.2 -

189 7.3); 6.8 months in group 2 (95%CI, 3.9-9.6) and 8.3 months in group 3 (95%CI, 5.7-10.9). HR for

190 group 2 vs group 1 was 0.60 (95%CI, 0.35 – 1.02). HR for group 3 vs group 1 was 0.54, (95%CI,

191 0.32–0.91). Total p-value was 0.067. Kaplan-Meier curves for PFS according to duration of ADT

192 response category in AA treated patients are shown in figure 5a. Among patients treated with AA,

193 median PFS for group 1 was 5.9 (95%CI, 3.8 – 7.9), for group 2 was 8.2 (95%CI, 5.6 – 10.8) and for

194 group 3 was 11.4 (95%CI, 8.6 – 14.1). Probability of being progression-free at 12 months was

195 10.1%, 31.6% and 44.9%, respectively. HR for group 2 vs group 1 was 0.50 (95% CI, 0.29-0.85). HR

196 for group 3 vs group 1 was 0.35 (95% CI, 0.21-0.60). Total p-value was 0.001. Kaplan-Meier curves

197 for PFS according to duration of ADT response category in E treated patients are shown in figure

198 5b. In patients treated with E, median PFS for group 1 was 6.0 (95%CI, 4.5-7.4), for group 2 was 9.6

199 (95%CI, 4.9–14.3) and for group 3 was 17.6 (95%CI, 7.0–28.2). Probability of being progression-

200 free at 12 months was 24.3%, 41.2% and 53.5%, respectively. HR for group 2 vs group 1 was 0.65

201 (95% CI, 0.34-1.25). HR for group 3 vs group 1 was 0.40 (95% CI, 0.19-0.82). Total p-value was

202 0.041.

203 The multivariable analysis (adjusted for the same variables used in OS analysis) demonstrated that

204 setting (HR for post-decetaxel vs docetaxel-naïve 1.50, 95%CI 1.04-2.18, p=0.031), ECOG PS HR for

205 PS1 vs PS0 1.51; 95%CI 1.05-2.15, p=0.025), baseline PSA (HR for higher vs lower PSA 1.50,95%CI

206 1.04-2.14) and duration of ADT response HR for group 2 vs group 1 0.54, 95%CI 0.33 - 0.89, HR for

207 group 3 vs group 1 0.45, 95%CI 0.27 - 0.74, p=0.007) are independent variables associated with the

208 PFS (table 3).

209

Discussion

210

211 Our analysis showed that a longer duration of response to ADT is associated with better outcomes

212 in CRPC patients receiving NHAs (E or AA). The subgroup analyses showed consistent effect for

213 docetaxel-naïve group and for both E and AA groups. We demonstrated a significant difference

214 between the three groups divided according to the duration of ADT response: the group who

215 responded longer to ADT (> 36 months) showed a better prognosis in terms of both OS and PFS.

216 In recent years, life expectancy of mCRPC patients has considerably increased, due to the

217 introduction of new drugs t including NHAs (AA[5,6] and E[7,8]), chemotherapy (Docetaxel[3] and

218 Cabazitaxel[4]) and Radium-223[9]. A critical challenge remains the lack of prognostic and predictive

219 biomarkers able to guide therapeutic choices and to assist clinicians in patient risk stratification.

220 Some prognostic models have been proposed and are used in clinical practice[10-17]. In particular,

221 according to the updated version of Halabi's model[13] the independent variables correlating with

222 survival in CRPC patients are: opioid use, LDH levels, site of disease, ECOG PS, haemoglobin, ALP

223 and PSA levels. Recently, Armstrong at colleagues (xx e xx) conducted a final 5-yr survival analysis of

224 PREVAIL trial in men with chemotherapy-naïve mCRPC from the enzalutamide and placebo arms. They

225 developed and validated a prognostic model for overall survival identifying 3 risk groups for predicting 1-, 2-

226 , and 3-years survival probabilities. According thise model the independent variables correlating with OS in

227 chemotherapy-naïve mCRPC are: number of bone metastases, pattern of spread (no liver metastases

228 versus any liver metastases), baseline pain, NLR value, harmoglobin, albumin, ALP, LDH and PSA levels.

229 Nowadays, it is well established that the shift from castration sensitive PC to CRPC is due to the

230 activation of both androgen receptor (AR)-dependent pathways and mechanisms not dependent

231 on AR signaling[27]. In the former case, there is an adaptation of neoplastic cells to a

232 microenvironment with low levels of androgens by overexpression of enzymes able to produce

233 androgens[28], AR overexpression[29], AR gene mutation[2] and expression of AR variant of splicing[30].

234 NHAs interfere with AR pathway and mechanisms of resistance to ADT: AA acetate acts as a potent

235   inhibitor of the PC androgens synthesis[31,32], while E binds and inhibits AR translocation inside the

236   nucleus[33]. Considering these mechanisms, ADT response duration can be considered as an index of

237   hormone responsiveness of disease and there is a strong rationale to study its role as a prognostic

238   factor during NHAs.

239   In addition to the primary analysis, in our multivariable analysis we evaluated all the variables of

240   Halabi's model. The value of baseline PSA and ECOG PS were independent variables for OS, while

241   chemotherapy setting, baseline PSA and ECOG PS were independent variables for PFS. The limited

242   sample size did not allow to show a statistical significance for the other factors included in Halabi's

243   nomogram, but our results confirmed the most recent literature data concerning the prognostic

244   role of the duration of response to ADT[18-26].

245   While the available literature evaluated patients mostly treated with AA, our study included

246   patients treated with AA or E in similar percentages (54.9% and 45.1% respectively), although

247   unbalanced between the docetaxel-naïve and post-docetaxel settings. In the subgroup analysis, a

248   significant difference in OS between the three groups was demonstrated only in patients treated

249   with AA, whereas for E there was not a significant difference in survival probability. However, the

250   subgroup analysis was conducted with exploratory intent and was not adequately powered for

251   each subgroup. Furthermore, we found a statistically significant difference in PFS among groups of

252   patients with different ADT duration both in AA and E subgroups, supporting the prognostic role of

253   ADT duration relevancy both for AA and E. The analysis of Hung et al.[26] conducted in 80 patients,

254   compared the outcomes of AA and E after ADT but no differences were detected. Considering the

255   aforementioned limitations, although we cannot exclude a similar effect in patients treated with E,

256   the results of our study suggests that the outcome of patients treated with AA is significantly

257   better in patients with a response to ADT longer than 12 months, compared to patients with a

258   shorter duration of response. This result can be explained due to the specific mechanism of action

259 of AA, that acts as CYP17A1 inhibitor and also as an AR antagonist[34]. D4-AA, one of the most

260 important metabolite of AA, is a strong AR antagonist with an activity comparable to E[23]. The

261 wider action of AA on AR pathway signalling compared with E could prove the most important

262 activity of AA in a disease with higher hormone responsiveness. However, the retrospective

263 nature, the absence of a validation dataset and the relatively limited number of patients in our

264 study only allow us to generate hypotheses for future studies.

265 Additionally, we compared PFS and OS of patients chemotherapy pretreated and chemotherapy-

266 naive. Li and colleagues[23] and Davies and colleagues' [24] populations included only patients pre-

267 treated with Docetaxel. Both studies showed a significant role of a longer duration of response to

268 ADT as a predictive factor of response to NHAs. We found a statistically significant benefit in OS

269 and PFS in the subgroup of patients who achieved a greater duration of response to ADT and

270 received NHAs in the docetaxel naïve setting, while the difference did not reach statistical

271 significance in docetaxel pre-treated patients. The limited statistical power of the subgroup

272 analysis could be the simplest explanation of this difference. However, another explanation could

273 be the influence of Docetaxel on AR. Preclinical data showed that taxanes may impair AR activity

274 by interfering with AR signaling pathway, blocking the polymerization of microtubules and AR

275 nuclear translocation therefore reducing AR-induced gene expression[35,36]. Evidence from two

276 clinical studies showed that Docetaxel in mCPRC patients causes a down regulation of AR

277 expression[37,38] possibly influencing the outcome of subsequent NHAs therapy.

278 In conclusion, we showed that the duration of response to androgen-deprivation therapy is an

279 independent prognostic factor for better OS and PFS in CRPC patients treated with NHAs. This can

280 be an important starting point for other studies planned to identify patients with a greater risk of

281 primary resistance to NHAs therapies. This is a crucial challenge for the future, in order to choose

282   the most effective therapy for each patient and consequently to improve survival and reduce

283   health care costs.

284

285

286

287

288

289 **References**

290 1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and

291   androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer

292   J Clin 1972; 22:232-40.. doi: 10.3322/canjclin.22.4.232.

293 2. Tucci M, Scagliotti GV, Vignani F. Metastatic castration-resistant prostate : time for innovation.

294   Future Oncology 2015;11(1):91-106. doi: 10.2217/fon.14.145.

295 3. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus

296   prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol

297   2008; 26:242-5.doi: 10.1200/JCO.2007.12.4008.

298 4. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for

299   metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a

300   randomised open-label trial. Lancet 2010; 376:1147-54.doi: 10.1016/S0140-6736(10)61389-X.

301 5. Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-

302   resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised,

303   double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983-92.doi:

304   10.1016/S1470-2045(12)70379-0.

305 6. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus

306   prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer

307   (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled

308   phase 3 study. Lancet Oncol 2015; 16:152-60.doi: 10.1016/S1470-2045(14)71205-7.

309 7. Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in Men with Chemotherapy-naive

310   Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL

311   Study. Eur Urol 2017; 71:151-154.doi: 10.1016/j.eururo.2016.07.032.

312 8. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after

313   chemotherapy. N Engl J Med 2017; 367:1187-97. doi: 10.1056/NEJMoa1207506.

314 9. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic

315   prostate cancer. N Engl J Med 2013; 369:213-23.doi: 10.1056/NEJMoa1213755.

316 10. Berry W. R., Laszlo J, Cox E., et al.Prognostic factors in metastatic and hormonally unresponsive

317   carcinoma of the prostate. Cancer 1979;44(2):763–775.

318 11. Kantoff W.P. et al.Hydrocortisone with or without mitoxantrone in men with hormone-

319   refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J. Clin.

320   Oncol.1999;17(8):2506-2513. doi:10.1200/JCO.1999.17.8.2506.

321 12. Halabi S. et al.Prognostic model for predicting survival in men with hormone-refractory
322   metastatic prostate cancer. J. Clin. Oncol.2003;21(7):1232–1237.

323 13. Halabi S. et al. Updated prognostic model for predicting overall survival in first-line
324   chemotherapy for patients with metastatic castration-resistant prostate cancer.J . Clin.
325   Oncol.2014; 32(7):671–677. doi:10.1200/JCO.2013.52.3696.

326 14. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive
327   metastatic prostate cancer after castration. J Clin Oncol. 2002;20(19):3972-3982.
328   doi:10.1200/JCO.2002.11.021.

329 15. Armstrong AJ, Garrett-Mayer ES, Yang YC, et al. A contemporary prognostic nomogram for
330   men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer
331   Res. 2007;13(21):6396-6403. doi:10.1158/1078-0432.CCR-07-1036.

332 16. Armstrong AJ, Garrett-Mayer E, de Wit R, et al. Prediction of survival following first-line
333   chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res.
334   2010;16(1):203-211. doi:10.1158/1078-0432.CCR-09-2514.

335 17. Halabi S, Lin CY, Small EJ, et al. Prognostic model predicting metastatic castration-resistant
336   prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst.
337   2013;105(22):1729-1737. doi:10.1093/jnci/djt280.

338 18. Giacinti S. et al.Duration of response to first androgen deprivation therapy, time to castration
339   resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer
340   patients treated with abiraterone acetate.Anticancer. Drugs 2017;28(1):110–115. doi:
341   10.1097/CAD.0000000000000434.

342 19. Loriot Y. et al.Prior long response to androgen deprivation predicts response to next-
343   generation androgen receptor axis targeted drugs in castration resistant prostate cancer.Eur. J.
344   Cancer 2015;51(14):1946–1952. doi: 10.1016/j.ejca.2015.06.128.

345 20. McKay R.R, Werner L, Fiorillo M, et al. Predictors of duration of abiraterone acetate in men
346   with castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2016;19(4):398-405.
347   doi:10.1038/pcan.2016.31.

348 21. Oudard S, Kheoh TS , Yu M. et al.Impact of prior endocrine therapy on radiographic
349   progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic
350   castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. J Clin Oncol 2017;
351   32:4_suppl, 14-14. doi: 10.1016/j.eururo.2015.10.021.

352   22. Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME. Secondary hormonal
353   therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011;9(2):95-
354   103. doi:10.1016/j.clgc.2011.06.006.

355   23. Li JR, Chiu KY, Wang SS, et al. Effectiveness of Deferred Combined Androgen Blockade Therapy
356   Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate
357   Cancer Patients after Docetaxel. Front Pharmacol. 2017;8:836. Published 2017 Nov 22.
358   doi:10.3389/fphar.2017.00836.

359   24. Davies RS, Smith C, Button MR, et al. What Predicts Minimal Response to Abiraterone in
360   Metastatic Castrate-resistant Prostate Cancer?. Anticancer Res. 2015;35(10):5615-5621.

361   25. Afshar M, Al-Alloosh F, Pirrie S, et al. Predictive factors for response to abiraterone in
362   metastatic castration refractory prostate cancer. Anticancer Res. 2015;35(2):1057-1063.

363   26. Hung J, Taylor AR, Divine GW, et al. The Effect of Time to Castration Resistance on Outcomes
364   With Abiraterone and Enzalutamide in Metastatic Prostate Cancer. Clin Genitourin Cancer.
365   2016;14(5):381-388. doi:10.1016/j.clgc.2016.03.021.

366   27. Buttigliero et al. Understanding and Overcoming the Mechanisms of Primary and Acquired
367   Resistance to Abiraterone and in Castration Resistant Prostate. Cancer Treat Rev.
368   2015;41(10):884-92. doi: 10.1016/j.ctrv.2015.08.002.

369   28. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen
370   therapy. Nat Med. 2004;10:33–9. doi:10.1038/nm972.

371   29. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal
372   androgens to testosterone in androgen-independent. Cancer Res. 2006;66:2815–25. doi:
373   10.1158/0008-5472.CAN-05-4000.

374   30. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from
375   splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res.
376   2009;69(1):16-22. doi:10.1158/0008-5472.CAN-08-2764.

377   31. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene
378   expression persist after testosterone suppression: therapeutic implications for castration-
379   resistant prostate cancer. Cancer Res. 2007;67(10):5033-5041. doi:10.1158/0008-5472.CAN-
380   06-3332.

381   32. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo
382   steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res.
383   2008;68(15):6407-6415. doi:10.1158/0008-5472.CAN-07-5997.

384 33. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions
385   converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28(7):778-808.
386   doi:10.1210/er.2007-0019.

387 34. Yin L, Hu Q. CYP17 inhibitors-, C17,20-lyase inhibitors and multi-targeting agents. Nat Rev Urol.
388   2014 Jan;11(1):32-42. doi: 10.1038/nrurol.2013.274. Epub 2013 Nov 26.

389 35. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear
390   accumulation of the androgen receptor predicts clinical responses in metastatic prostate
391   cancer. Cancer Res. 2011;71(18):6019-6029. doi:10.1158/0008-5472.CAN-11-1417.

392 36. Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding the
393   microtubule   expressway   to   the   nucleus.   Cancer   Res.   2012;72(18):4611-4615.
394   doi:10.1158/0008-5472.CAN-12-0783.

395 37. Jiang J, Huang H. Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate
396   Cancer. Mol Cell Pharmacol. 2010;2(1):1-5.

397 38. Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of docetaxel following treatment
398   with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. Ann Oncol.
399   2012;23(11):2943-2947. doi:10.1093/annonc/mds119.
400

401 **Legends to figures**

402 **Figure 1.** Kaplan-Meier curves for overall survival (panel A) and for progression-free survival (panel
403 B) according to duration of ADT response category in the whole cohort of patients.

404 **Figure 2.** Kaplan-Meier curves for overall survival according to duration of ADT response category
405 in docetaxel-naïve setting (panel A) and docetaxel-pretreated setting (panel B).

406 **Figure 3** Kaplan-Meier curves for progression-free survival according to duration of ADT response
407 category in docetaxel-naïve setting (panel A) and docetaxel-pretreated setting (panel B).

408 **Figure 4.** Kaplan-Meier curves for overall survival according to duration of ADT response category
409 in patients treated with abiraterone (panel A) and in patients treated with enzalutamide (panel B).

410 **Figure 5.** Kaplan-Meier curves for progression-free survival according to duration of ADT response
411 category in patients treated with abiraterone (panel A) and in patients treated with enzalutamide
412 (panel B).